Syndecan-1 signals independently of beta1 integrins during Raji cell spreading.
Syndecan-1-expressing Raji lymphoid cells (Raji-S1 cells) bind and spread rapidly when attaching to matrix ligands that contain heparan sulfate-binding domains. However, these ligands also contain binding sites for integrins, which are widely known to signal, raising the question of whether the proteoglycan core protein participates in generation of the signal for spreading. To address this question, the spreading of the Raji-S1 cells is examined on ligands specific for either beta1 integrins, known to be present on the Raji cells, or the syndecan-1 core protein. The cells adhere and spread on invasin, a ligand that activates beta1 integrins, the IIICS fragment of fibronectin, which is a specific ligand for the alpha4beta1 integrin, or mAb281.2, an antibody specific for the syndecan-1 core protein. The signaling resulting from adhesion to the syndecan-specific antibody appears integrin independent as (i) the morphology of the cells spreading on the antibody is distinct from spreading initiated by the integrins alone; (ii) spreading on the syndecan or integrin ligands is affected differently by the kinase inhibitors tyrphostin 25, genistein, and staurosporine; and (iii) spreading on the syndecan-specific antibody is not disrupted by blocking beta1 integrin activation with mAb13, a beta1 inhibitory antibody. These data demonstrate that ligation of syndecan-1 initiates intracellular signaling and suggest that this signaling occurs when cells expressing syndecan-1 adhere to matrix ligands containing heparan sulfate-binding domains.
Lebakken
C S
CS
Program in Cellular and Molecular Biology, University of Wisconsin-Madison, Madison, Wisconsin, 53706, USA. acraprae@facstaff.wisc.edu
McQuade
K J
KJ
Rapraeger
A C
AC
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001402:B-Lymphocytes / Q000166:cytology* / Q000502:physiology; D002448:Cell Adhesion / Q000187:drug effects / Q000502:physiology; D048429:Cell Size / Q000187:drug effects / Q000502:physiology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D016326:Extracellular Matrix Proteins / Q000502:physiology; D019833:Genistein / Q000494:pharmacology; D019812:Heparan Sulfate Proteoglycans / Q000502:physiology; D006801:Humans; D019012:Integrin beta1 / Q000276:immunology / Q000378:metabolism*; D016393:Lymphoma, B-Cell; D008562:Membrane Glycoproteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D009500:Neutralization Tests; D010446:Peptide Fragments / Q000235:genetics / Q000378:metabolism; D011509:Proteoglycans / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology*; D019311:Staurosporine / Q000494:pharmacology; D053668:Syndecan-1; D053667:Syndecans; D014407:Tumor Cells, Cultured; D020032:Tyrphostins / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D004791:Enzyme Inhibitors; D016326:Extracellular Matrix Proteins; D019812:Heparan Sulfate Proteoglycans; D019012:Integrin beta1; D008562:Membrane Glycoproteins; D010446:Peptide Fragments; D011509:Proteoglycans; D011993:Recombinant Fusion Proteins; C508241:SDC1 protein, human; D053668:Syndecan-1; D053667:Syndecans; D020032:Tyrphostins; C079836:tyrphostin 25; D019833:Genistein; D019311:Staurosporine